Risk factors

Lineage Cell Therapeutics (LCTX) risk factors

Item 1A of every Lineage Cell Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open LCTX in Gloom →
Lineage Cell Therapeutics' chart, financials and news, free in your browser.Open LCTX in Gloom →
  • FY2025 10-K risk factors
    87 risks25 new13 dropped23 reworded

    Company faces clinical and regulatory hurdles for nascent allogeneic cell therapies requiring surgical delivery. R&D spending increased to $17.7 million in 2025.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors
    75 risks

    Company is heavily reliant on Roche for OpRegen development and revenue.

    Filed Mar 10, 2025